Ximeclav 500 mg + 125 mg is a combination antibiotic that merges Cefuroxime Axetil, a second-generation cephalosporin, with Clavulanic Acid, a beta-lactamase inhibitor. This formulation is effective against a broad spectrum of bacteria, including those producing beta-lactamase enzymes that can render certain antibiotics ineffective.